Skip to content
Syenza News
  • Innovative Tech
  • Diseases
  • Health Policy
  • HTA
  • Data Analysis
  • Clinical Practice
  • Contributors
BACK TO MAIN SITE
MR-107A-02: Revolutionizing Non-Opioid Pain Man...

By Rene Pretorius

May 12, 2025

Viatris Inc.
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
Prevention Valuation: Fund Health, Not Just Savings
FDA AI Drug Approval
HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel
Trump Science Publishing Critique: Analyzing Political Interference and Metho...
South Africa NHI Bill Court Ruling Calls for Scrutiny
Implementing Health Technology Assessment in Oman
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Wegovy CVS Deal: Hybrid Market Access Strategy Insights
Empowering Health: The Role of Self-Care and NCDs in Global Health Policy
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure
« Previous 1 … 8 9 10 11 12 … 74 Next »

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER

This is required.
This is required.
This is required.

SERVICES

  • HEOR
  • Global Market Access
  • Dynamic Intelligence
  • Glossary of Terms
  • Advanced Degrees

QUICK LINKS

  • About
  • Case Studies
  • Insights
  • Art of Science
  • Careers
  • Contact Us
  • Copyright Notice
  • Privacy Policy
  • Terms & Conditions
schedule a meeting
LINKEDIN
TWITTER
© 2025 Syenza™. All rights reserved.

Made with by Frogiez

schedule a meeting